April 7, 2019
  • Marco Blei

Supplementary protection certificates: clarifications from the EU Court of Justice

In its judgment on Case C-443/17 of March 21, 2019, the European Court of Justice ruled on a significant patent issue following a preliminary ruling under Article 267 of the Treaty on the Functioning of the European Union (TFEU) from the High Court of Justice (England & Wales). Specifically, the issue concerned the possibility of considering a marketing authorization (MA) granted for a new formulation of an existing and authorized active ingredient, the first MA for the purposes of granting a supplementary protection certificate (SPC).


The United Kingdom’s Comptroller General of Patents rejected Abraxis Bioscience’s application for the granting of the SPC for the nab-paclitaxel medicinal product for treating cancer, marketed under the name “Abraxane”. In fact, the Comptroller declared that the medicinal product was missing one of the conditions necessary for granting the SPC as required by Article 3 (d) of Regulation (EC) no. 469/2009.

Specifically, according to the Comptroller, the MA granted for nab-paclitaxel could not be considered the product’s first MA subject to the SPC application. This decision is based on the fact that the old active ingredient, paclitaxel, contained in nab-paclitaxel within a new formulation with albumin, was already covered by the MA. Abraxis therefore challenged this decision before the EU High Court of Justice.

Conditions for granting an SPC 

According to the above-mentioned Regulation (EC) no. 469/2009 (Article 3), an SPC can be granted if the product, subject to the application, holds a currently valid MA (b) and if the MA is the first authorization for the medicinal product (d).

Given these conditions, the Court of Justice questioned whether the MA granted for the new formulation of an old active ingredient could be considered a new MA and therefore the first MA for that product. In order to solve this issue, the Court had to assess whether the new formulation of an existing active ingredient (including additional ingredients) represented a new and distinct product.

According to the Court of Justice the product corresponds with the active ingredient 

On this point, the Court confirmed a restrictive interpretation of the concept of “product”, including in its definition only the active ingredient. Ingredients that do not have any therapeutic effect (such as albumin in the present case) are therefore excluded since they act exclusively as vectors for the active ingredient, for example paclitaxel within the new formulation of the ingredient nab-paclitaxel. Consequently, nab-paclitaxel cannot be included within the definition of “product” according to the Regulation (EC) 469/2009 and therefore cannot constitute a distinct product from the old active ingredient.

These considerations give rise to the general principle according to which the new formulation of an old active ingredient does not constitute a new product, distinct from the previous product, when an active ingredient is combined with a substance lacking therapeutic effect and is therefore not considered within the concept of a ”product”.

The MA granted to the new formulation is not the first MA for the product 

Finally, the Court analyzed the possibility of considering the MA granted to the new formulation of an old active ingredient as the first authorization pursuant to Article 3 (d) of the referenced Regulation and it reached the conclusion that it was not possible to recognize the authorization as the first if the old active ingredient had already been covered by the MA.

This would, in fact, be contrary to the aim of the Regulation regarding SPCs, which aims to promote the protection of pharmaceutical research leading to the first placement on the market of an active ingredient or a combination of active ingredients, in a balanced approach to encourage investments in research for new pharmaceutical products and protect public health, as specified by the Court. Therefore, in such circumstances, the conditions for the granting of an SPC are not met.

< Back to blog
Welcome to the Portolano Cavallo Life Sciences blog focusing on legal development and key legal issues affecting the life sciences and healthcare industry.
Read more
Our highly-ranked team of professionals will provide news, insights and multidisciplinary commentary on the hottest and most recent regulatory, transactional and contentious aspects of the pharmaceutical, bio-tech, med-tech, food supplement and healthcare world with an eye on its digital transformation and technological developments.

This blog will be a place for focusing on digital health, telemedicine and artificial intelligence, as well as more traditional topics: from the protection of intellectual properties to performance of clinical trials, from the market access to advertising and competition issues, from internal and criminal investigations to M&A and venture capital transactions.

October 6, 2023
CBD products: the Administrative Court suspended until October 24 the recent Decree of the Italian Ministry of Health listing cannabidiol for oral use among narcotic drugs, due to the lack o...
October 4, 2023
The Guidelines for regulating contractual relations between universities and research institutes and private sponsors were adopted by the relevant Italian Ministries following the amendment ...
September 21, 2023
CBS products: from September 20th, compositions for oral administration of cannabidiol obtained from Cannabis sativa extracts shall be considered as narcotic drugs in Italy, as they have bee...
July 27, 2023
Payback on medical devices: Italian government announces extension of payment deadline to October 30, 2023
July 21, 2023
On July 21, 2023, the Italian Ministry of Health published new guidelines on health advertising of self-medication drugs (OTC) and non-prescription drugs (SOP), including advertising on new ...
Search by...
Follow us on
Follow us on